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STUDY QUESTION: Do maternal serum levels of progesterone metabolites early in pregnancy correspond to an increased risk for very
preterm delivery prior to 32 weeks?
SUMMARY ANSWER: Maternal serum levels of 11-deoxycorticosterone (DOC) measured during the late first trimester or early second
trimester correlate with an increased risk for preterm delivery prior to 32 weeks, and the correlation becomes stronger when the ratio of
DOC to 16-alpha-hydroxyprogesterone was measured.
WHAT IS KNOWN ALREADY: Progesterone is a pro-gestational steroid hormone that has been shown to decrease the risk of preterm
birth in some pregnant women. Progesterone is metabolized by the body into various metabolites including members of the mineralocorticoid
and glucocorticoid families. Our group has previously demonstrated that some progesterone metabolites enhance myometrial contractility
in an ex vivo system, while others result in myometrial relaxation. The current exploratory study was designed to determine if pre-specified
metabolites of progesterone measured early in pregnancy were associated with a woman’s risk for delivery prior to 32 weeks, which is referred
to as a very preterm delivery.
STUDYDESIGN, SIZE, DURATION: The Building Blocks of Pregnancy Biobank (BBPB) is a biorepository at Indiana University (IU) that fol-
lows women prospectively through their pregnancy. A variety of biospecimens are collected at various time points during a woman’s pregnancy.
Women participating in the IU BBPB who were enrolled after 8 weeks’ gestation with pregnancy outcome data were eligible for participation.
PARTICIPANTS/MATERIALS, SETTING, METHODS:Women delivering prior to 37 weeks (preterm) and at or after 37 weeks (term)
who had blood samples collected during the late first trimester/early second trimester and/or during the early third trimester were identified.
These samples were then processed for mass spectroscopy, and the amount of progesterone and progesteronemetabolites in the samples were
measured. Mean values of each measured steroid metabolite were calculated and compared among women delivering at less than 32 weeks,
less than 37 weeks and greater than or equal to 37 weeks. Receiver operating characteristic (ROC) curves were constructed and threshold
levels determined for each compound to identify a level above or below which best predicted a woman’s risk for delivery prior to 32 and
prior to 37 weeks. Mann–Whitney U nonparametric testing with Holm–Bonferroni correction for multiple comparisons was utilized to identify
steroid ratios that could differentiate women delivering spontaneously at less than 32 weeks from all other pregnancies.
MAIN RESULTS AND THE ROLE OF CHANCE: Steroid hormone levels and pregnancy outcome data were available for 93 women;
28 delivering prior to 32 weeks, 40 delivering between 32 0/7 and 36 6/7 weeks and 25 delivering at or greater than 37 weeks: the mean
gestational age at delivery within the three groups was 27.0, 34.4 and 38.8 weeks, respectively. Among women delivering spontaneously at
less than 37 weeks, maternal 11-deoxycorticosterone (DOC) levels drawn in the late first trimester/early second trimester were significantly
associated with spontaneous preterm delivery prior to 32 weeks; a threshold level of 47.5 pg/ml had 78% sensitivity, 73% specificity and an
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AUC of 0.77 (P =0.044). When DOC levels were analyzed as a ratio with other measured steroid hormones, the ratio of DOC to 16-alpha-
hydroxyprogesterone among women delivering spontaneously prior to 37 weeks was able to significantly discriminate women delivering prior
to 32 weeks from those delivering at or greater than 32 weeks, with a threshold value of 0.2 with 89% sensitivity, 91% specificity and an AUC
of 0.92 (P =0.002). When the entire study cohort population was considered, including women delivering at term and women having an
iatrogenic preterm delivery, the ratio of DOC to 16-alpha-hydroxyprogesterone was able to discriminate women delivering spontaneously
prior to 32 weeks from the rest of the population at a threshold of 0.18 and 89% sensitivity, 59% specificity and an AUC of 0.81 (P =0.003).
LIMITATIONS, REASONS FOR CAUTION: This is a discovery study, and the findings have not been validated on an independent cohort.
To mitigate issues with multiple comparisons, we limited our study to pre-specified metabolites that are most representative of the major
metabolic pathways for progesterone, and adjustments for multiple comparisons were made.
WIDER IMPLICATIONS OF THE FINDINGS: Spontaneous preterm birth is increasingly being recognized to represent a common end
pathway for a number of different disease phenotypes that include infection, inflammation, premature rupture of the membranes, uterine
over distension, cervical insufficiency, placental dysfunction and genetic predisposition. In addition to these phenotypes, longitudinal changes
in the maternal–fetal hypothalamic–pituitary–adrenal (HPA) axis also likely contribute to a significant proportion of the disease burden of
spontaneous preterm birth. Here, we demonstrate that differential production of steroid metabolites is associated with very early preterm
birth. The identified biomarkers may hint at a pathophysiologic mechanism and changes in thematernal–fetal dyad that result in preterm delivery.
The early identification of abnormal changes in HPA axis metabolites may allow for targeted interventions that reverse the aberrant steroid
metabolic profile to a more favorable one, thereby decreasing the risk for early delivery. Further research is therefore required to validate and
extend the results presented here.
STUDY FUNDING/COMPETING INTEREST(S): Funding for this study was provided from theOffice of the Vice Chancellor for Research
at IUPUI, ‘Funding Opportunities for Research Commercialization and Economic Success (FORCES) grant’.
Both A.S.P. and C.A.G. are affiliated with Nixxi, a biotech startup. The remaining authors report no conflict of interest.
TRIAL REGISTRATION NUMBER: Not applicable.
Key words: preterm delivery / prematurity / biomarker / steroids / progesterone / 11-deoxycorticosterone / 16-alpha-
hydroxyprogesterone / pregnancy
WHAT DOES THIS MEAN FOR PATIENTS?
Being born before 32 weeks (preterm birth is delivery less than 37 weeks) can cause a wide number of long-term health issues for children or
even the death of newborn babies. At the moment, doctors do not have many ways of helping them know which pregnant women will deliver
their babies prematurely. Being able to know which women might have a preterm delivery is important so that various treatments could be used
to decrease the chance of these women delivering early.
In this study, the authors show that measurement of two different steroid hormones in the blood of women early in pregnancy might be able
to predict which women will deliver prior to 32 weeks, which is also called very preterm delivery. The authors intend to do more research to find
out if treating women who are thought to be likely to deliver before term can make delivering early less likely.
Introduction
Preterm birth continues to be a significant global health problem.
Approximately 1 in 10 pregnant women deliver prematurely in the
USA, with worldwide rates rising up to 18% (World Health Organiza-
tion, 2019). Preterm birth has widespread societal impact: newborns
can have lifelong medical complications, families deal with emotional
strain and financial costs rise for health plans and employers. Among
babies born prematurely, those with very or extremely preterm
delivery (less than 32 weeks’ and 28 weeks’ gestation, respectively)
have the most severe complications and highest associated healthcare
costs annually (WorldHealthOrganization, 2019). In theUSA, preterm
delivery less than 32 weeks is associated with an 80-fold increase
in infant mortality compared to women delivering between 39 and
41 weeks’ gestation (175.5 versus 2.1 deaths per 1000 live births)
(Mathews and MacDorman, 2012). Despite technological advances,
the rate of very preterm delivery (less than 32 weeks’ gestation)
remains unchanged (Heron, 2012). Across the USA, the annual
societal economic costs of preterm birth and associated care are
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estimated at $26 billion (Behrman and Butler, 2007). The lack of
progress in reducing the rate of early preterm delivery has hampered
efforts to improve downstream sequelae, including disparities in infant
mortality rates.
One barrier to the reduction of spontaneous preterm delivery
(sPTD) less than 32 weeks is the development of an accurate risk
stratification approach for women early in pregnancy. The current stan-
dard of care is to identify women at risk for sPTD based on a history
of premature delivery in a prior pregnancy. However, this approach
has been estimated to miss up to 93% of sPTD annually (Khalifeh
and Berghella, 2016). A fundamental challenge to risk stratification is
that the pathogenesis of preterm delivery is multifactorial. A recent
multicenter analysis identified nine potential phenotypes associated
with the common final pathway of uterine contractility and sPTD
(Manuck et al., 2015). The diversity of etiologies of preterm delivery
presents a barrier for any single testing approach to identify all women
at risk of preterm delivery.
A long-standing phenotype associated with sPTD involves the
maternal/fetal hypothalamic–pituitary–adrenal (HPA) axis. Central
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to this phenotype is the role of corticotropin-releasing hormone
(CRH) in leading to a cascade of events culminating in delivery
(McLean et al., 1995; McGrath et al., 2002; Sandman et al., 2006). The
production of placental CRH has been suggested to be an integrative
pathway which allows prenatal stressors to influence gestational length
(Sandman, 2018). A longitudinal study of 203 pregnancies revealed that
elevations in maternal cortisol as early as 15 weeks’ gestation were
associated with increased third trimester CRH concentrations and
preterm birth rates (Sandman et al., 2006). However, a large secondary
analysis did not find that CRH alone was predictive of recurrent
preterm delivery when assessed early in pregnancy at 16–20 weeks
(Sibai et al., 2005).
Regulation of preterm labor through the HPA axis is subject to
hormonal influences. Endogenous steroids, such as glucocorticoids,
have been identified as key promoters of placental CRH gene expres-
sion (Robinson et al., 1988; Karalis et al., 1996; Whittle et al., 2001;
Wang et al., 2013), while progesterone has been suggested to mitigate
this effect. Glucocorticoids and progesterone have been associated
with opposing influences on uterine contractility (Whittle et al., 2001).
Metabolites of progesterone have been shown to have varying efficacy
in mitigating uterine contractility, with some metabolites increasing
contractility, unlike progesterone (Kubli-Garfias et al., 1979; Patil et al.,
2015). Despite the known influence of these molecules on sPTD, there
has not been a systematic evaluation of endogenous steroid hormones
derived from progesterone. In this exploratory study, we sought to
evaluate a range of steroid hormones derived from progesterone with
both mineralocorticoid and glucocorticoid characteristics for associ-
ation with sPTD less than 32 weeks. We hypothesized that multiple
steroid hormones may influence sPTD potentially through modulation
of placental CRH.
Materials and Methods
In order to investigate the relationship between endogenous steroid
hormones and the timing of preterm birth, metabolomic analysis
was performed on prospectively collected plasma specimens from a
cohort of women enrolled in a single-institution pregnancy registry.
The Building Blocks of Pregnancy Biobank at the Indiana University
School of Medicine (IU BBPB) is a longitudinal, prospective pregnancy
biorepository with a range of maternal specimens collected as part
of an organized research program. Subjects enrolled in the IU BBPB
have biologic specimens collected through convenience sampling every
trimester over the course of their pregnancy, in addition to clinical data
on current and prior obstetric outcomes. Use of biological specimens
and associated data was covered by existing Institute Review Board
approval for the IU BBPB (IRB #1011003384).
We sought to examine the association of sPTD less than 32 weeks
with three endogenous steroid pathways: progestogens, glucocorti-
coids and mineralocorticoids. Steroid molecules were selected for
quantification based on their characterization as immediate proges-
terone derivatives or downstream metabolites with mineralocorticoid
or glucocorticoid activity. The steroid molecules chosen for quantifi-
cation included progesterone, 17-hydroxyprogesterone (17-OHP),
11-deoxycortisol, cortisol, 11-deoxycorticosterone (DOC), 17-deoxy
cortisol, 20α-dihydroprogesterone, 17α,20α-dihydroxyprogesterone,
16α-hydroxyprogesterone (16α-OHP), 6α-hydroxyprogesterone
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(6α-OHP) and 6β-hydroxyprogesterone (6β-OHP). Prospectively
collected plasma specimens from women enrolled in the IU BBPB
were obtained for the analysis. Plasma samples were divided into two
epochs for analysis based on when in pregnancy they were collected;
Epoch 1 (late first trimester/early second trimester) and Epoch 2
(early third trimester). Specimens were obtained from all available
subjects who delivered preterm (less than 37 weeks) for the initial
analysis. Specimens from subjects delivered at term (greater than or
equal to 37 weeks) were also collected during the same time period
and processed identically. Subjects delivered at term were matched
for BMI and excluded for use of steroids or anticoagulants. A targeted
subset of the steroid molecules was compared between the term and
preterm specimens.
A targeted metabolomics approach, developed at Gaikwad
Steroidomics Lab, was used to quantify endogenous progestogen,
glucocorticoid and mineralocorticoid steroids using ultraperformance
liquid chromatography-tandem mass spectrometry (UPLC/MS-MS)
analysis. The frozen human plasma samples were processed using an
assay validated on the MS platform (Gaikwad, 2013). Briefly, 1–2-ml
aliquots of plasma were adjusted to pH 7.0 and subject to solid phase
extraction with methanol. The methanol fraction was subjected to
UPLC/MS-MS analysis. Analytical separations on the UPLC system
were conducted with C18 or phenyl columns (1× 100 mm) at a flow
rate of 0.15 ml/min. The gradient was started with 100% A (0.1%
formic acid in H2O) and 0% B (0.1% formic acid in CH3CN), changed
to 80% A over 10 min, followed by a 10-min linear gradient to 0%
A, resulting in a total separation time of 20 min. The elutions from
the UPLC column were introduced to the mass spectrometer. All MS
experiments were performed using electrospray ionization (ESI) in
positive ion and negative ion mode, with an ESI-MS capillary voltage
of 3.0 kV, an extractor cone voltage of 2 V and a detector voltage
of 650 V. The following MS conditions were used: desolvation gas at
600 l/h, cone gas flow at 60 l/h, desolvation temperature at 200◦C
and source temperature 100◦C. Using pure reference standards,
the multiple reaction monitoring method (MRM) for UPLC/MS-MS
operation was previously generated. Pure standards were used to
optimize the UPLC-MS/MS conditions prior to analysis and make
calibration curves. Elutions from the UPLC column were analyzed in
the MRMmode, and resulting data were processed using MassLynx 4.1
software (Waters Corporation, Milford, MA, USA).
Quantified steroids were evaluated for association with sPTD less
than 32 weeks using standard statistical methods. Statistical analy-
sis was performed using SPSS Statistics Version 26 software (IBM,
Armonk, NY, USA). Receiver operating characteristic (ROC) curves
were used to identify steroid hormone patterns capable of distinguish-
ing women who would subsequently have sPTD less than 32 weeks
from women who would deliver at or greater than 32 weeks’ ges-
tation (delivery at 32 0/7–36 6/7 weeks or greater than or equal
to 37 weeks). The area under the ROC curve (AUROC) was used
to compare the predictive ability of individual and combinations of
steroid hormones in Epochs 1 and 2. The Mann–Whitney U test with
Holm–Bonferroni correction for multiple comparisons was utilized to
determine if there was a significant difference in median values of
steroid ratios. The initial screening of steroid hormones was per-
formed using an ‘enriched cohort’ of only subjects with sPTD less
than 37 weeks (comparison of sPTD less than 32 weeks compared to
sPTD in the 32 0/7–36 6/7 weeks cohort). Subsequent analyses also
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Table I Demographic data for all 93 subjects in the study.
GA at delivery (weeks)
.........................................................................................................................
Parameter Less than 32 32 0/7–36 6/7 Greater than or equal to 37 0/7 P value
.......................................................................................................................................................................................
N (%) 28 (30%) 40 (43%) 25 (27%)
Age (years) 25.5 27.6 23.6 0.04
GA at delivery (weeks, mean) 27 34.4 38.8 <0.001
BMI (kg/m2) 32 32 27 0.06
History of PTD, % 36% 43% 13% 0.51
Race1 (%) 0.45
Caucasian 13 (46%) 23 (57%) 14 (56%)
African American 14 (50%) 17 (43%) 10 (40%)
Asian 0 0 1 (4%)
Not reported 1 (4%) 0 0
Composite maternal2 0.5 (0–1.0) 1.0 (0–2.0) 0 (0–0) <0.001
Composite antepartum3 1.0 (0–1.0) 1.0 (0–2.0) 0 (0–0) <0.001
1Analysis by chi-square; all others by ANOVA.
2Median (interquartile range: IQR) number of pre-specified maternal co-morbidities (see methods).
3Median (IQR) number of pre-specified antepartum complications (see Materials and methods).
GA= gestation age, PTD=preterm delivery
Table II Demographic data for women experiencing spontaneous PTD at two time points in the enriched cohort.
Parameter sPTD less than 32 weeks sPTD greater than or
equal to 32 weeks
P value
.......................................................................................................................................................................................
N (%) 17 (50%) 17 (50%)
Age (years) 24.6 26.6 0.32
GA at delivery (weeks, mean) 26.8 34.4 <0.001
BMI (kg/m2) 30.9 29.5 0.58
History of PTD, % 47% 35% 0.73
Race (%) 0.591
Caucasian 8 (47%) 9 (53%)
African American 8 (47%) 8 (47%)
Not reported 1 (6%) 0
Composite maternal2 0 (0–1.0) 1.0 (0–2.0) 0.12
Composite antepartum3 1.0 (0–1.0) 0 (0–1.0) 0.82
1Analysis by chi-square; all others by ANOVA.
2Median (IQR) number of pre-specified maternal co-morbidities (see Materials and methods).
3Median (IQR) number of pre-specified antepartum complications (see Materials and methods).
sPTD= spontaneous preterm delivery. The enriched cohort experienced sPTD at less than 37 weeks.
included subjects with iatrogenic PTD and full-term delivery (greater
than or equal to 37 weeks’ gestation) to assess performance of the
molecules in a generalized population (comparison of sPTD less than
32 weeks versus all other subjects). Patient demographic and clinical
outcome data were analyzed using standard statistical approaches. A
P value <0.05 was considered significant. A composite of maternal
co-morbidities was pre-specified for analysis between cohorts: thyroid
disorder, diabetes, respiratory disorder, hypertension, seizure disorder,
cardiac disease, renal disease, hematologic disease, autoimmune dis-
ease, liver disease, cancer, mental health disorder, endocrine disorder,
neurologic disorder and infectious diseases. Similarly, a composite
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of antepartum complications was pre-specified for analysis between
cohorts: gestational hypertension, pre-eclampsia, HELLP (hemolysis,
elevated liver enzyme, low platelet count) syndrome, gestational dia-
betes, incompetent cervix, hyperemesis, peripartum depression, oligo-
hydramnios/polyhydramnios, fetal demise, growth restriction, placen-
tation disorders and hydrops.
Results
Ninety-three subjects from the BBPB were included in the study. Of
these, 68 delivered preterm (less than 37 weeks) and 25 delivered
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Table III Analysis of individual steroids by GA within the enriched cohort of women with sPTD at less than 37 weeks and
ability to predict sPTD at less than 32 weeks in the enriched cohort.
Steroid hormone Steroid concentration (pg/ml)1 ROC curve
................................................................. ...........................................
sPTD less than
32 weeks
sPTD greater than or
equal to 32 weeks
AUC (95% CI) P value
.......................................................................................................................................................................................
Progesterone Epoch 1 5546± 9726 945.8± 1274.6 0.288 (0.046–0.530) 0.111
Epoch 2 652.5± 277.9 6284± 12057.8 0.8 (0.593–1.00) 0.050
17-Hydroxyprogesterone Epoch 1 901.1± 592.3 981.3± 1012.3 0.485 (0.214–0.756) 0.909
Epoch 2 1273.6± 535.7 988± 758.6 0.293 (0.068–0.519) 0.176
11-Deoxycortisol Epoch 1 616.3± 506.8 483.5± 463.7 0.434 (0.167–0.701) 0.621
Epoch 2 1459.2± 565 679.9± 938.3 0.133 (0–0.294) 0.016
Cortisol Epoch 1 69 217± 41 083 61 727± 40 916 0.434 (0.176–0.692) 0.621
Epoch 2 130 686± 85 464 77 717± 53 034 0.280 (0–0.577) 0.150
11-Deoxycorticosterone Epoch 1 43.8± 64.8 110.3± 126.7 0.768 (0.551–0.984) 0.044
Epoch 2 155± 84.8 236.1± 241.3 0.547 (0.293–0.801) 0.760
17-Deoxycortisol Epoch 1 1500.1± 2203.7 1465± 1330 0.591 (0.329–0.853) 0.494
Epoch 2 3262.2± 2080.5 1974.5± 2055.8 0.300 (0–0.623) 0.190
20α-Dihydroprogesterone Epoch 1 3266.3± 3228.8 1667.7± 1168.8 0.364 (0.090–0.638) 0.305
Epoch 2 3988.4± 2947.4 3388.6± 2515.1 0.467 (0.179–0.754) 0.827
17α,20α-Dihydroxyprogesterone Epoch 1 454.8± 338.8 398.1± 292.5 0.444 (0.175–0.714) 0.676
Epoch 2 458.2± 233.2 455.3± 342.1 0.413 (0.096–0.731) 0.570
16α-Hydroxyprogesterone Epoch 1 442.7± 284.2 411.6± 499.7 0.384 (0.130–0.638) 0.382
Epoch 2 872.6± 439.5 681.9± 611.7 0.333 (0.057–0.609) 0.275
6α-Hydroxyprogesterone Epoch 1 815.3± 910.4 638.5± 384.2 0.545 (0.266–0.825) 0.732
Epoch 2 1217± 322.6 743.6± 347 0.160 (0–0.343) 0.026
6β-Hydroxyprogesterone Epoch 1 401.6± 606.8 187± 272.5 0.444 (0.177–0.712) 0.676
Epoch 2 1313.2± 691.2 658.7± 679.1 0.213 (0–0.428) 0.061
1Values are mean± SD.
P value is reported for the AUC of the receiver operating characteristic (ROC) curve for each steroid hormone. P values in bold indicate significance.
Epoch 1: blood collected in the late first trimester/early second trimester Epoch 2: blood collected in the early third trimester.
full term (at or greater than 37 weeks). Twenty-eight subjects (41%)
within the preterm group delivered in the very preterm period (less
than 32 weeks), while the remaining 40 (59%) delivered between
32 0/7 and 36 6/7 weeks. Thirty-four subjects were determined to
have had iatrogenic PTD (34/68, 50%). The most common indication
for iatrogenic PTD was pre-eclampsia (20/34, 59%), followed by
preterm premature rupture of the membranes (6/34, 18%). Samples
were obtained from subjects at a mean (± SD): gestational age of
15.5± 3.4 weeks in Epoch 1 (n =71), and at 29.6± 3.2 weeks in
Epoch 2 (n =45).
Patient demographics were similar between the preterm and
full-term groups (Table I). There were no differences in race or
history of prior PTD between the preterm and full-term groups.
Significant variance in maternal age was observed between groups,
with the full-term group having younger subjects. Similarly, the
full-term group had lower rates of maternal co-morbidities and
antepartum complications than either preterm group (Table I). As
described in the Materials and Methods, the initial analyses were
performed in the ‘enriched cohort’ of subjects with only sPTD less
than 37 weeks’ gestation (of the 68 women prior to 37 weeks’
gestation, 34 delivered spontaneously). Subsequent analyses included
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all subjects (sPTD, iatrogenic PTD and full-term delivery). Table II
provides a comparison of demographics between subjects with sPTD
less than 32 weeks and greater than or equal to 32 weeks’ gestation
in the enriched cohort. Aside from gestational age at delivery, no
significant differences were present in the demographics of the two
groups.
All of the targeted steroid molecules could be quantified as
intended using the validated MS methods. Analysis of individual steroid
molecules within the ‘enriched cohort’ of subjects with sPTD less than
37weeks is described in Table III. In Epoch 1, DOCwas identified as the
only molecule with a significant AUROC, which was 0.768 (P =0.044)
for the association with sPTD less than 32 weeks within the group
of women delivering preterm. A threshold 11-deoxycorticosterone
concentration of 47.5 pg/ml was associated with 78% sensitivity
and 73% specificity for identification of pregnancies at risk for sPTD
less than 32 weeks (AUROC 0.768, P =0.044, Table III). Within
the sPTD less than 37 weeks ‘enriched cohort’, subjects with 11-
deoxycorticosterone values below the same threshold had a mean
gestational age of delivery of 27.7± 5.6 weeks, while those with
values above the threshold delivered at 32.2± 3.5 weeks on average
(P =0.045). In Epoch 2, 11-deoxycortisol (AUROC 0.133; P =0.016)
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Figure 1 Prediction of spontaneous preterm delivery less
than 32 weeks. Area under the ROC curve (AUROC with 95%
CI) for 11-deoxycorticosterone (DOC) to selected steroid ratios for
prediction of spontaneous preterm delivery (sPTD) in the enriched
cohort of all sPTDs. DOC steroid ratios with significant predictive
ability (ROC curve P value) are indicated by a carat symbol (∧). Ratios
with a significant difference in median values between sPTD less than
32 and sPTD greater than or equal to 32 weeks after correction for
multiple comparison (Mann–Whitney U nonparametric testing with
Holm–Bonferroni correction for multiple comparisons) are indicated
by asterisks (∗∗). Enriched cohort: comprises only subjects who deliv-
ered less than 37 weeks gestation.
and 6α-OHP (AUROC 0.160; P =0.026) were each significantly
associated with sPTD <32 weeks.
DOC was the only steroid to have significant predictive ability
in Epoch 1 (AUROC 0.768, P =0.044) and was thus utilized for
examination of steroid ratios. Ratios of DOC to the other steroids
were assessed to determine if they could provide an improvement in
prediction of sPTD less than 32 weeks within Epoch 1 (Fig. 1). Within
the enriched cohort of sPTD less than 37 weeks, ROC curve analysis
identified DOC/progesterone (AUROC 0.800, P =0.033), DOC/-
cortisol (AUROC 0.818, P=0.017), DOC/17-deoxycortisol (AUROC
0.773, P =0.048), DOC/20α-dihydroprogesterone (AUROC 0.798,
P =0.025) and DOC/16α-hydroxyprogesterone (AUROC 0.919,
P =0.002) as meeting statistical significance in Epoch 1 (Fig. 1). The
ratio of DOC/16α-OHP, having the highest AUROC, demonstrated
89% sensitivity and 91% specificity for prediction of PTD less than
32 weeks at a threshold value of 0.2. Subjects within the enriched
cohort whose DOC/16α-OHP values fell below the threshold had a
mean gestational age of delivery of 26.4± 4.7 weeks, while those with
values above the threshold delivered at 32.8± 3.4 weeks (P =0.002).
Within Epoch 2, ratios of DOC/11-deoxycortisol (AUROC 0.829,
P =0.033) and DOC/6β-hydroxyprogesterone (AUROC 0.817,
P =0.045) were significantly associated with sPTD <32 weeks (Fig. 1).
Further analysis of the median DOC steroid ratios between sPTD less
than 32 and sPTD greater than or equal to 32 week groups in Epochs
1 and 2 was performed using the Mann–Whitney U test with Holm–
Bonferroni correction to account for multiple comparisons (Fig. 1).
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The analysis revealed that only the DOC/16α-OHP ratio remained
significant (P =0.02 after correction for multiple comparison). Figure 1
illustrates that only the DOC/16α-OHP ratio had both significant
predictive characteristics and a significant difference in median values
between the sPTD< 32 and sPTD≥ 32 weeks groups.
Based on the AUROC within the enriched cohort, the performance
of the DOC/16α-OHP biomarker was next assessed in the entire
study population, which also included subjects with iatrogenic PTD
and full-term deliveries. DOC/16α-OHP was able to successfully
predict pregnancies that would result in sPTD less than 32 weeks
when measured in the late first trimester/early second trimester in this
general population (Fig. 2a: AUROC 0.805; P =0.003). A threshold
DOC/16α-OHP ratio of 0.18 was associated with 89% sensitivity,
59% specificity for identification of pregnancies at risk for sPTD less
than 32 weeks. The DOC/16α-OHP biomarker did not predict iatro-
genic PTD less than 32 weeks (Fig. 2b: AUROC 0.669; P =0.172).
Within the entire study population, subjects with a DOC/16α-OHP
ratio below the threshold value in Epoch 1 delivered on average at
33± 6.1 weeks, while those with a ratio above the threshold delivered
at 35.6± 4.2 weeks (P =0.04). A similar analysis of DOC alone as a
biomarker in the entire study population in Epoch 1 was not associated
with a significant difference in gestational ages at birth (30.7± 4.8
versus 32± 3.7 weeks; P =0.325). Additionally, the Mann–Whitney
U test confirmed a significant difference in the median DOC/16α-
OHP ratio between the sPTD less than 32 week group compared
to the remainder of the study population (P =0.003). In Epoch 2,
the ratio of DOC/11-deoxycortisol (AUROC 0.738, P =0.019) was
predictive of any PTD <32 weeks in the general population. The
mean gestational age at delivery for subjects below the threshold value
(0.18) for DOC/11-deoxycortisol was 31.7± 2.7 weeks compared to
33.8± 1.7 weeks for individuals above the threshold value (P =0.007).
Discussion
Our study demonstrates a relation between progesterone metabolism
into the mineralocorticoid and glucocorticoid pathways and timing
of sPTD. In the study cohort, DOC measured during the late first
trimester/early second trimester was the only steroid hormone eval-
uated that was able to distinguish subjects with a significantly increased
rate of sPTD less than 32 weeks from those delivering spontaneously
between 32 0/7 and 36 6/7 weeks’ gestation. The discriminatory
ability of this molecule was further improved when its measured
concentration was compared to other compounds in Epoch 1, as a
ratio. In particular, the ratio of DOC to a number of other molecules
(progesterone, cortisol, 17-deoxycortisol, 20α-dihydroprogesterone
and 16α-OHP) each resulted in a higher AUROC compared to the
AUROC for DOC alone. The ratio of DOC/16α-OHP performed
the best (AUROC0.919), followed byDOC/cortisol (AUROC0.818).
In Epoch 2, the ratio of DOC/11-deoxycortisol showed the best
ability to distinguish subjects destined for sPTD less than 32 weeks
(AUROC 0.829). The predictive ability of these molecules dimin-
ished when they were applied to a general population with outcomes
including iatrogenic PTD and full-term deliveries. Nonetheless, the
DOC/16α-OHP ratio in Epoch 1 continued to distinguish subjects who
would subsequently have sPTD less than 32weeks with statistical signif-
icance (AUROC 0.805, P =0.003) within the entire general population.
The DOC/16α-OHP ratio in Epoch 1 was also the only biomarker that
Progesterone metabolites and very preterm delivery 7
Figure 2 Assessment of performance of the DOC/16α-hydroxyprogesterone biomarker in the entire study population. A ROC
curve of DOC/16α-OHP in Epoch 1 for prediction of sPTD less than 32 weeks from all subjects. AUROC 0.805 (0.644–0.965); P =0.003. B ROC
curve of DOC/16α-OHP in Epoch 1 for prediction of iatrogenic PTD less than 32 weeks from all subjects. AUROC 0.669 (0.417–0.922); P =0.172.
16α-OHP: 16α-hydroxyprogesterone. Epoch 1: blood collected in the late first trimester/early second trimester. Entire study population: all subjects,
including women having an iatrogenic preterm delivery and women delivering at term.
met statistical significance for difference in median values between the
sPTD< 32 weeks and sPTD ≥32 weeks groups after correction for
multiple comparisons (P =0.02).
The goal of this study was to evaluate progesterone-derived
molecules in the classic steroid metabolism pathway as candidate
predictors of preterm birth. Progesterone is recognized as the
hormone primarily responsible for the maintenance of pregnancy
through a variety of pro-gestational effects. Progesterone is part of
a larger metabolic pathway and is further metabolized by CYP450
21A2 (21-hydroxylase) and CYP450 17A1 (17a-hydroxylase) into
a variety of mineralocorticoid and glucocorticoid molecules. While
progesterone has beneficial effects for an ongoing pregnancy, the
impact of its metabolites can be varied. Patil et al. have previously
shown that the endogenous progesterone metabolites 16α-OHP
and 6β-OHP have opposing effects on oxytocin-induced uterine
contraction frequency (Patil et al., 2015). The extent of progesterone
metabolism into these opposing compounds is dependent upon
cytochrome P450 enzyme isoform, the expression of which may vary
between individuals (Quinney et al., 2017). These observations suggest
that the ‘progestogen milieu’ may define a subgroup of women with a
pro-contractile phenotype who have greater susceptibility to preterm
labor when exposed to an additional stimulus (infection, dehydration,
trauma, etc.). Similarly, increased concentrations of a glucocorticoid,
cortisol, have been associated with preterm labor (Sandman et al.,
2006).
The maternal/fetal HPA phenotype has been extensively studied as
a pathway leading to sPTD. The HPA phenotype postulates that CRH
influences the timing of delivery (McLean et al., 1995; McGrath et al.,
2002; Sandman et al., 2006). CRH is a peptide hormone produced
by placental trophoblasts and released into both maternal and fetal
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compartments. CRH in the maternal circulation binds to CRH binding
protein (CRH-BP), which limits its biological effects. However, CRH in
the fetal circulation has been shown to bind to CRH receptors (CRH-
R1, CRH-R2) in the myometrium, and to stimulate the production of
prostaglandins and estrogens (via dehydroepiandrosterone: DHEA), all
of which increase uterine contractility. Increased CRH concentrations
have been observed as early as 16 weeks and are most prominent
shortly before delivery (McLean et al., 1995). The regulatory mech-
anisms that influence placental CRH production are influenced by
endogenous steroids. Glucocorticoids have been identified as a key
stimulator of placental CRH (Robinson et al., 1988; Karalis et al., 1996;
Whittle et al., 2001; Wang et al., 2013). The rising placental CRH
further stimulates fetal adrenal production of cortisol (glucocorticoid),
in a positive-feedback loop, which culminates in parturition (Robinson
et al., 1988).
Although the association between elevated levels of CRH and timing
of preterm birth is established in the literature, identification of women
with theHPA phenotype early in gestation has been elusive. Production
of maternal plasma CRH occurs along a higher trajectory in women
who have sPTD compared to those with term delivery (McGrath
et al., 2002). A study by Hill et al. identified white blood cell count
and maternal CRH as the most accurate biomarkers for preterm birth
within 48 h at less than 28 and greater than 28 weeks, respectively
(Hill et al., 2008). Notably, cortisol was included in this analysis but did
not outperform the other biomarkers. Another study supported the
utility of CRH as a biomarker of preterm birth in underrepresented
ethnic groups when drawn at 22 to 24 weeks’ gestation (Ruiz et al.,
2016). In contrast, a secondary analysis of a preterm birth prevention
study performed by the Eunice Kennedy Shriver National Institute of
Child Health and Human Development Maternal-Fetal Medicine Units
8 Patil et al.
Figure 3 Progesterone metabolism by major cytochrome P450 enzymes denoting major and minor products.Asterisk (∗) denotes
minor metabolite of progesterone from the respective enzymatic reactions. CYP: cytochrome P450, 6β-OHP: 6β-hydroxyprogesterone, 17α-OHP:
17-hydroxyprogesterone.
Network did not find that CRH alone was predictive of recurrent
preterm delivery when assessed at 16 to 20 weeks (Sibai et al., 2005).
A longitudinal study of 203 pregnancies revealed that elevations in
maternal cortisol as early as 15 weeks’ gestation were associated with
increased third trimester CRH concentrations and preterm birth rates
(Sandman et al., 2006). Another study found a trend of decreased
progesterone and increased CRH in maternal plasma in the early third
trimester to be associated with preterm birth (Stamatelou et al., 2009).
Despite the known role of glucocorticoids as a promoter of CRH,
there has not been a broader evaluation of the glucocorticoid class
of molecules as predictors of preterm birth.
Of the steroid biomarkers identified in our study, DOC is a metabo-
lite of progesteronewith partial mineralocorticoid properties. Notably,
it has been observed to be increased in the presence of DHEA-sulfate,
which is associated with increased CRH. 16α-OHP is a minor product
that serves as a marker for the extent of progesterone metabolism,
and 11-deoxycortisol is a precursor to the glucocorticoid cortisol. Our
data suggest that a decreased ratio of (DOC/16α-OHP) is an early
indicator of an imbalance between mineralocorticoid and glucocorti-
coid pathways later in pregnancy, and subsequent preterm delivery.
16α-OHP has been documented to be a minor product of proges-
terone metabolism by cytochrome P450 enzymes, including CYP3A,
CYP17 and CYP21 (Fig. 3) (Mizrachi et al., 2011; Storbeck et al., 2011;
Quinney et al., 2017). 16α-OHP is unique in that it is not extensively
metabolized, whilemost other progesterone derivatives continue to be
modified into mineralocorticoids, glucocorticoids, estrogens or andro-
gens. As a result, 16α-OHP may serve as a marker of progesterone
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metabolism downstream and the studied DOC/16α-OHP ratio may
identify those women with enhanced progesterone metabolism and, as
such, an increased risk for preterm birth. The presence of DOC, the
major product of CYP21metabolism of progesterone, as a component
of the predictive algorithm suggests that progesterone metabolism
into pathways other than glucocorticoids is an important feature that
characterizes risk of preterm delivery. Notably, metabolism of pro-
gesterone by other major CYP enzymes produces pro-contractile
molecules. Progesterone metabolism by CYP3A produces 6β-OHP,
which increases uterine contractile frequency (Patil et al., 2015). CYP17
metabolism of progesterone leads to the production of cortisol, which
is known to stimulate placental CRH and uterine contractility as part
of the maternal–fetal HPA axis phenotype.
The high societal costs associated with preterm birth have driven the
development of new approaches for diagnosis and treatment. Preven-
tion of a single very preterm delivery can account for the cost of care
for 40 full-term infants over the first year of life. Currently, screening
for risk of preterm delivery is largely based upon personal history of
preterm delivery in a prior pregnancy. However, many women are not
able to be screened because they lack prior obstetric history: 40% of
pregnancies occur in nulliparous women (first time pregnancies) where
no prior obstetric history exists (Martin et al., 2013). Also notable is
that 70% of pregnant women delivering prematurely in their second
pregnancy had full-term deliveries in their first pregnancy (Laughon
et al., 2014). In recent years, a variety of ‘-omics’ technologies (pro-
teomics, genomics) have been used to develop laboratory-basedmeth-
ods for the prediction of sPTD (Saade et al., 2016; Jelliffe-Pawlowski
Progesterone metabolites and very preterm delivery 9
et al., 2018; Ngo et al., 2018; McElrath et al., 2019). While these tests
provide advances in risk stratification, the mechanistic relationship of
their biomarkers to the onset of preterm labor is not well established.
The diversity of clinical phenotypes for preterm birth undermines the
plausibility of any single test providing a comprehensive risk assessment
early in pregnancy before the phenotype is evident; rather, new tests
should be designed to characterize a sub-population of women with a
single phenotype early in pregnancy that may portend an increased risk
of preterm delivery and provide insight into appropriate interventions.
Our study has several limitations that we acknowledge. First, the
study was designed as an exploratory analysis of a pre-specified range
of molecules and is subject to multiple-comparisons error. We have
sought to minimize this risk by using the Holm–Bonferroni correction
to reduce false-positive results and correlating findings to supporting
data in the literature. Our study was not powered to directly compare
various biomarker combinations; instead, the ROC curve for each
biomarker was compared to the line of no-discrimination (random
guessing). A future study with a pre-planned hypothesis is needed to
confirm the observed associations. Second, our sample size was limited
and generalization of the study findings should be made with caution.
We utilized an established academic pregnancy biobank to create an
enriched study population to increase the feasibility of this discovery
study. The 28 very preterm (<32 weeks) births in our enriched cohort
is roughly equivalent to the number expected from screening a general
population of 1400 pregnancies (1:50 incidence). We applied our
findings from the analysis of the enriched cohort to all subjects in
our study (including iatrogenic PTD and full-term deliveries) to better
approximate the performance of the DOC/16α-OHP biomarker in a
general population. Third, we infer an association between alterations
in the DOC/16α-OHP ratio and the HPA phenotype although this is
not formally tested.Our data analysis revealed a pattern of alteredmin-
eralocorticoid/glucocorticoid concentrations that plausibly influences
downstream markers associated with preterm labor. However, we did
not perform a global assessment of molecules previously associated
with the HPA phenotype and fetal health, such as CRH orDOC sulfate,
respectively. In addition, as the study was not designed to do so, we
were not able to survey womenwith a validated tool to assess maternal
psychosocial stressors to determine if these stressors are associated
with altered progesterone metabolism. Future validation studies will
also seek to determine if CRH or DOC sulfate, in combination with
other measured steroid metabolites, may be able to predict a woman’s
risk for preterm birth. In addition, mechanistic studies are needed to
formally link the DOC/16α-OHP ratio to changes in CRH activity.
Longitudinal changes in the maternal–fetal HPA axis have been
shown to predispose a pregnant woman to sPTD (Sandman et al.,
2006). This study has demonstrated that quantification of progesterone-
derived molecules as early as the late first trimester may provide
insight into which pregnancies are at risk for very preterm delivery
(<32 weeks). The DOC/16α-OHP ratio appears to be a particularly
promising tool for risk stratification of women early in pregnancy based
on our findings.We believe that DOC/16α-OHP is an early biomarker
for a mineralocorticoid/glucocorticoid imbalance that influences CRH
and the HPA phenotype of sPTD. An ‘abnormal’ DOC/16α-OHP
ratio may define a subset of women susceptible to environmental
or infectious insults culminating in sPTD. More work is needed to
understand the mechanisms linking DOC and 16α-OHP to sPTD; this
insight may provide an opportunity to develop targeted therapeutic
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strategies to improve clinical care. Further studies are needed to
validate these findings and create a tool for early identification of
pregnancies at risk for very preterm delivery.
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